Anthony Fauci, director of the National Institutes of Allergy and Infectious Diseases at the National Institutes of Health, said Friday that the development of the new coronavirus vaccine is progressing well and that a vaccine is expected to enter clinical research within a month and a half. However, mass production of the vaccine will take at least a year.
Fauci said at a press conference held by the U.S. Department of Health and Human Services the same day, the National Institute of Allergy and Infectious Diseases and the U.S. biotech company Modena co-operation in the development of the new coronavirus vaccine as scheduled, even faster than expected.
According to reports, from the identification of pathogens to the start of a phase i clinical trial as soon as two or three months. U.S. researchers have previously obtained data from viral gene sequences published by their Chinese counterparts, successfully injecting the gene into Modner’s messenger RNA (mRNA) platform to begin guiding protein synthesis.
After injecting genes into mRNA platforms to guide protein synthesis, the researchers have injected these proteins into mice to induce immunogenicity, and the next step is to complete regulatory matters, with the vaccine expected to enter clinical research in a month and a half, about a week faster than originally planned, Fauci said.
Modena announced on the 24th that it has shipped the first batch of mRNA-1273, the company’s new coronavirus vaccine, to the National Institute of Allergy and Infectious Diseases for the first phase of clinical trials.
However, Fauci admits that the first phase of the clinical trial takes three or four months to verify the safety and effectiveness of the vaccine, followed by a Phase II clinical trial involving hundreds of subjects, “even at rocket speed, it takes another six months”, so mass production of the vaccine would take a year or even a year and a half.
The vaccine may not solve the problems faced in recent months, but it should focus on the future, Fauci said.